HC Wainwright & Co. analyst Yi Chen reiterates First Wave BioPharma (NASDAQ:FWBI) with a Buy.
Endava Faces Analyst’s Cautious Outlook Amid Industry Uncertainty, Price Target Reduced
Susquehanna analyst James E Friedman reiterated a Positive rating on the shares of Endava Plc (NYSE: DAVA),